Bringing the price down really is going to impact those people who either dont have insurance for [GLP-1s] and have been paying out of pocket, or alternatively, those people who have chosen to go the route of purchasing them as compounded versions, says Cristy Gallagher, with the STOP Obesity Alliance at George Washington Universitys Milken Institute School of Public Health
DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Eli Lilly, MSD, Novo Nordisk, and Sanofi and has received research operating funds from Boehringer Ingelheim-Eli Lilly Diabetes Alliance, MSD, AstraZeneca, and Novo Nordisk
Switched from another brand and noticed improved regularity and mood stability right away
Thermo Fisher)
Clinical trials showing the medications effectiveness typically ran for 68 weeks or longer
There is a company currently called Agentix that is investigating a new CB1 receptor antagonist as an antiobesity drug and, very unfortunately, its OTC and only has a market cap of 3 million or else this entire article would be about why everyone should short it